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Cyphellophora guyanensis (n 15), other Cyphellophora species (n 11), Phialophora europaea (n 43), and other Phialo-
phora species (n 12) were tested in vitro against nine antifungal drugs. TheMIC90s across all of the strains (n 81) were, in
increasing order, as follows: posaconazole, 0.063g/ml; itraconazole, 0.5g/ml; voriconazole, 1g/ml; micafungin, 1g/ml;
terbinafine, 2g/ml; isavuconazole, 4g/ml; caspofungin, 4g/ml; fluconazole, 8g/ml; amphotericin B, 16g/ml.
Although dermatophytes and yeasts account for themajority ofsuperficial and cutaneous fungal infections, members of the
black yeast-like fungi are reported regularly (2, 18).Humid indoor
environments such as bathrooms and swimming pools (14, 15)
are potential reservoirs for black yeast infections. Cyphellophora
and Phialophora species are black yeast-like fungi that form a phy-
logenetic “europaea clade” within the order Chaetothyriales (9)
and are recovered from human skin and nails (8, 18). Phialophora
europaea was found in 27% of positive cultures with black yeasts
(18) which are found simultaneously with dermatophytes on the
skin of diabetic patients (11). The taxonomy of the genus Cyphel-
lophora has recently been revised, and 11 independent species
were recognized in the “europaea clade,” i.e., Cyphellophora lac-
iniata, C. vermispora, C. pluriseptata, C. suttonii, C. fusarioides, C.
pauciseptata, C. guyanensis, Phialophora ambigua, P. oxyspora, P.
reptans, and P. europaea (9, 12). Cyphellophora laciniata, C. pluri-
septata (5, 10), C. pauciseptata, and P. ambigua thus far have been
isolated exclusively from superficial lesions in human infections
(7, 9, 12), while C. fusarioides originated from bronchoalveolar
lavage fluid from a patient after heart bypass surgery (19).Cyphel-
lophora suttonii was originally isolated from a phaeohyphomy-
cotic lesion in a dog’s ear (1) but also from ulcerating skin lesions
in a patient with sarcoidosis (17). At present, there is no informa-
tion available on the antifungal susceptibility profiles of Cyphello-
phora and its relatives. This study aimed to determine the in vitro
susceptibilities of a large collection of clinical and environmental
isolates ofCyphellophora and Phialophora species belonging to the
black yeast “europaea clade” to eight antifungal drugs and isavu-
conazole (13, 20, 21), a new triazole that currently is undergoing
phase III clinical trials.
A total of 81 strains were obtained from the Centraalbureau
voor Schimmelcultures (CBS; Utrecht, The Netherlands) Fungal
Biodiversity Centre, which included Cyphellophora guyanensis
(n 15),C. laciniata (n 3),C. pauciseptata (n 1),C. plurisep-
tata (n 3),Cyphellophora suttonii (n 1),C. vermispora (n 3),
Phialophora ambigua (n  1), P. europaea (n  43), P. oxyspora
(n 3), and P. reptans (n 8) (see Table S1 in the supplemental
material). The strains were obtained from human (n  55) and
animal (n 1) clinical samples, environmental samples (n 12),
plant materials (n  11), and unknown sources (n  2). The set
included all available ex-type strains of the species described and
was supplemented with newly isolated strains. In addition to
genotyping, species identity was confirmed by molecular charac-
terization of the internal transcribed spacer region, the partial
DNA-dependent RNA polymerase II largest-subunit gene, the
beta-tubulin gene, and the nuclear large-subunit rRNA gene (9,
12). Antifungal susceptibility testing was performed as described
in CLSI document M38-A2, with some modifications (6). Briefly,
isolates were cultured on potato dextrose agar in the dark (25°C)
for up to 7 days to induce sporulation. Inocula were prepared by
scraping the surface of the fungal colonies with a cotton swab
moistened with sterile physiological saline containing 0.05%
Tween 40. Large particles were allowed to settle for 5 min, and
then a suspension of spores was adjusted with a spectrophotome-
ter (Spectronic 20D; Milton Roy, Rochester, NY) to 68 to 71%
transmission (at 530 nm) and diluted 10-fold to yield a final inoc-
ulum of 1.5 104 to 5 104 CFU/ml. The test concentrations of
amphotericin B (Bristol-Myers Squibb, Woerden, The Nether-
lands), itraconazole (Janssen Research Foundation, Beerse, Bel-
gium), voriconazole (Pfizer Central Research, Sandwich, United
Kingdom), posaconazole (Schering-Plough, Kenilworth, NJ), isa-
vuconazole (Basilea Pharmaceutica International AG, Basel, Swit-
zerland), and terbinafine (Novartis Pharma, Basel, Switzerland)
ranged from 0.016 to 16 g/ml; those of fluconazole (Pfizer)
ranged from 0.063 to 64 g/ml; and those of caspofungin (MSD,
Haarlem, The Netherlands) and micafungin (Astellas Pharma,
Ibaraki, Japan) ranged from 0.008 to 8 g/ml. After 72 h of incu-
bation at 25°C, MICs and minimum effective concentrations
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TABLE 1 Geometric mean MICs, MIC ranges, MIC50s, and MIC90s obtained by susceptibility testing of antimycotic agents against Cyphellophora
and relatives
Organism (no. of strains/genotypea) and drug
MIC/MEC (g/ml)
Range 50% 90% Geometric mean
Total (n 81)
Amphotericin B 0.125–16 4 16 4
Fluconazole 2–16 8 8 27.655
Itraconazole 0.016–1 0.125 0.5 0.097
Voriconazole 0.063–2 0.25 1 0.323
Posaconazole 0.016–0.125 0.016 0.063 0.027
Isavuconazole 0.25–4 1 4 1.928
Caspofungin 0.25–8 1 4 1.116
Micafungin 0.008–4 0.125 1 0.07
Terbinafine 0.016–4 0.5 2 0.341
Cyphellophora guyanensis (n 15/group C4)
Amphotericin B 1–16 16 16 5.879
Fluconazole 4–16 8 16 23.516
Itraconazole 0.063–1 0.25 0.5 0.25
Voriconazole 0.25–1 0.5 1 0.5
Posaconazole 0.016–0.125 0.063 0.125 0.05
Isavuconazole 0.25–4 2 4 3.703
Caspofungin 1–4 1 2 1.361
Micafungin 0.008–1 0.031 0.25 0.037
Terbinafine 0.125–1 0.25 0.5 1.167
Cyphellophora laciniata (n 3/group A1)
Amphotericin B 1–4 NCb NC 1.587
Fluconazole 4–16 NC NC 25.398
Itraconazole 0.063–0.125 NC NC 0.079
Voriconazole 0.25–1 NC NC 0.63
Posaconazole 0.016–0.031 NC NC 0.02
Isavuconazole 1–2 NC NC 3.175
Caspofungin 1–4 NC NC 1.587
Micafungin 0.008–0.008 NC NC 0.008
Terbinafine 0.125–0.125 NC NC 0.5
Cyphellophora pauciseptata (n 1/group A6)
Amphotericin B 0.5 NC NC NC
Fluconazole 32 NC NC NC
Itraconazole 0.125 NC NC NC
Voriconazole 0.5 NC NC NC
Posaconazole 0.031 NC NC NC
Isavuconazole 2 NC NC NC
Caspofungin 0.5 NC NC NC
Micafungin 0.031 NC NC NC
Terbinafine 0.063 NC NC NC
Cyphellophora pluriseptata (n 3/groups C1, C2)
Amphotericin B 4–8 NC NC 6.35
Fluconazole 4–16 NC NC 40.317
Itraconazole 0.125–0.25 NC NC 0.157
Voriconazole 0.25–0.5 NC NC 0.315
Posaconazole 0.031–0.063 NC NC 0.039
Isavuconazole 1–2 NC NC 2.52
Caspofungin 2–8 NC NC 4
Micafungin 0.008–0.016 NC NC 0.01
Terbinafine 0.016–0.25 NC NC 0.316
Cyphellophora suttonii (n 1/group A4)
Amphotericin B 2 NC NC NC
Fluconazole 32 NC NC NC
Itraconazole 0.25 NC NC NC
Voriconazole 0.5 NC NC NC
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Organism (no. of strains/genotypea) and drug
MIC/MEC (g/ml)
Range 50% 90% Geometric mean
Posaconazole 0.063 NC NC NC
Isavuconazole 8 NC NC NC
Caspofungin 1 NC NC NC
Micafungin 0.25 NC NC NC
Terbinafine 2 NC NC NC
Cyphellophora vermispora (n 3/group A2)
Amphotericin B 0.5–1 NC NC 0.707
Fluconazole 8–8 NC NC 32
Itraconazole 0.063–0.5 NC NC 0.177
Voriconazole 0.5–2 NC NC 1
Posaconazole 0.031–0.063 NC NC 0.044
Isavuconazole 2–4 NC NC 5.657
Caspofungin 0.5–4 NC NC 0.707
Micafungin 0.063–1 NC NC 0.251
Terbinafine 0.063–0.063 NC NC 0.25
Phialophora ambigua (n 1/group C3)
Amphotericin B 8 NC NC NC
Flucon0azole 32 NC NC NC
Itraconazole 0.5 NC NC NC
Voriconazole 0.25 NC NC NC
Posaconazole 0.125 NC NC NC
Isavuconazole 1 NC NC NC
Caspofungin 4 NC NC NC
Micafungin 0.25 NC NC NC
Terbinafine 1 NC NC NC
Phialophora europaea (n 43/group E)
Amphotericin B 0.125–16 2 16 2.341
Fluconazole 2–16 4 8 21.246
Itraconazole 0.016–0.5 0.063 0.25 0.071
Voriconazole 0.125–1 0.25 0.5 0.25
Posaconazole 0.016–0.125 0.016 0.031 0.021
Isavuconazole 0.25–2 1 1 1.506
Caspofungin 0.25–4 1 2 1.065
Micafungin 0.008–4 0.25 1 0.167
Terbinafine 0.25–2 0.5 1 0.533
Phialophora oxyspora (n 3/group D)
Amphotericin B 4–16 NC NC 11.314
Fluconazole 4–8 NC NC 32
Itraconazole 0.25–0.25 NC NC 0.25
Voriconazole 0.5–1 NC NC 0.707
Posaconazole 0.016–0.125 NC NC 0.089
Isavuconazole 2–4 NC NC 8
Caspofungin 1–4 NC NC 4
Micafungin 0.5–2 NC NC 2
Terbinafine 0.5–2 NC NC 1.414
Phialophora reptans (n 8/group B)
Amphotericin B 1–16 NC NC 4
Fluconazole 4–8 NC NC 22.627
Itraconazole 0.016–0.125 NC NC 0.044
Voriconazole 0.063–0.5 NC NC 0.177
Posaconazole 0.016–0.063 NC NC 0.019
Isavuconazole 0.25–2 NC NC 1.414
Caspofungin 0.25–2 NC NC 0.917
Micafungin 0.008–0.5 NC NC 0.045
Terbinafine 0.008–0.063 NC NC 0.037
a Molecular groups are those of Feng et al. (12).
b NC, no comparison because10 strains per species were available for testing.
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(MECs) were determined visually by comparison of the growth in
the wells containing the drug with that of the drug-free control.
Quality control strains Paecilomyces variotii ATCC 22319, Can-
dida parapsilosis ATCC 22019, and Candida krusei ATCC 6258
were included in each assay run.
Two specieswith sufficient numbers of isolates (n10)were
included to calculate the MIC50 and MIC90 values, viz., Phialo-
phora europaea and Cyphellophora guyanensis (Table 1; see Table
S2 in the supplemental material). All of the strains of Cyphello-
phora and Phialophora tested had lowMICs of itraconazole, vori-
conazole, posaconazole, andmicafungin, whilemost of the strains
had high MICs of fluconazole and amphotericin B. The highest
geometric mean MICs were 27.6 g/ml of fluconazole, followed
by 4 g/ml of amphotericin B, and much lower geometric mean
MICs of the triazoles, echinocandins, and allylamine (isavucona-
zole, 1.9 g/ml; caspofungin, 1.1 g/ml; voriconazole, 0.3 g/ml;
terbinafine, 0.3 g/ml; itraconazole, 0.1 g/ml; micafungin, 0.07
g/ml; posaconazole, 0.03 g/ml). Posaconazole was the drug
with the best overall activity. The eight species for which few or
single isolates were available (P. ambiguaCBS 235.93;C. paucisep-
tata CBS 284.85; C. suttonii CBS 449.91; C. laciniata CBS 174.79,
CBS 190.61, and CBS 239.91; C. pluriseptata CBS 285.85, CBS
286.85, and CBS 109633; C. vermispora CBS 277.86, CBS 228.86,
and CBS 122852; P. oxyspora CBS 416.89, CBS 698.73, and CBS
124686; and P. reptans CBS 113.85, CBS 152.90, CBS 458.92, CBS
101467, CBS 110814, CBS 120903, CBS 120913, and CBS 123271)
yielded the lowest MICs of posaconazole, micafungin, itracona-
zole, and voriconazole (Table 1). In general, the MIC90s of itra-
conazole, voriconazole, and isavuconazole were at least 2 log2 di-
lution steps higher than those of posaconazole. The
environmental isolates of C. guyanensis had higher MICs of terbi-
nafine and isavuconazole than the clinical strains of P. europaea.
The two echinocandins showed marked differences in their
MECs; in most cases, micafungin had potent activity, with a geo-
metric mean MEC and MEC90 showing at least 2 log2 dilution
steps higher activity than caspofungin. These data are in agree-
ment with previously reported findings on the black yeasts Clado-
phialophora (3), Fonsecaea (16), and Rhinocladiella (4). There was
a significant difference (P 0.001) between theMICs of the eight
antifungals for P. europaea (group E), P. reptans (groupD), andC.
guyanenesis (group B) (Table 1). Phialophora europaea isolates,
when divided into skin and nail subgroups, showed no difference
in susceptibility (see Table S2 in the supplemental material). The
present paper provides the first antifungal susceptibility data on
clinical species of Cyphellophora and its relatives in the genus Phi-
alophora, which compose a phylogenetic “europaea clade” within
the order Chaetothyriales. The results suggest that the species in
this clade of black yeast-like organisms are susceptible in vitro to
the newer azoles and to micafungin; however, these in vitro data
still need to be complemented by clinical confirmation in vivo.
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